Phase 1 Study of Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm
To assess whether the effectiveness of a combination of transcatheter arterial
chemoembolization(TACE) and radiofrequency ablation(RFA) is superior to TACE and RFA alone
in treatment of patients with hepatocellular carcinoma(HCC)greater than 3 cm and to analyze
the factors affecting the outcomes.
The patients with HCC of 3 or fewer lesions, each 3cm greater in diameter entered this
randomized controlled trial. The primary end point was survival, and the secondary end
points were tumor response.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment
overall survival
5 years
Wang Qi Liang, MD,PhD
Study Chair
Dept. of Radiology
China: Ethics Committee
2001HCC
NCT00479050
January 2001
December 2006
Name | Location |
---|